ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,246.68
      0.48%
      US Tech 100
      17,844.00
      0.68%
      Dow Jones
      39,558.11
      0.32%
      Brent Oil
      82.41
      -0.17%
      Bitcoin
      61,413.44
      -0.22%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Enlivex Therapeutics Ltd (ENLV)

      7. Enlivex Therapeutics Ltd (ENLV) News

      ENLV

      Enlivex Therapeutics (ENLV)

      Enlivex Therapeutics Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ENLV
      DateTimeSourceHeadlineSymbolCompany
      2:09PMiHub NewswireFeaturedPOET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems
      11:00AMiHub NewswireFeaturedElement79 Gold Corp Reports Exceptionally High-Grade Results from Lucero
      04/29/20248:00AMGlobeNewswire Inc.Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsNASDAQ:ENLVEnlivex Therapeutics Ltd
      04/22/20248:00AMGlobeNewswire Inc.Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
      04/16/20244:55PMAllPennyStocks.comYet Another Biotech Stock Has Found Success During Tuesday's SessionNASDAQ:ENLVEnlivex Therapeutics Ltd
      04/16/20247:50AMGlobeNewswire Inc.Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
      04/11/20242:58PMGlobeNewswire Inc.Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisNASDAQ:ENLVEnlivex Therapeutics Ltd
      04/11/20248:05AMGlobeNewswire Inc.Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisNASDAQ:ENLVEnlivex Therapeutics Ltd
      02/07/20248:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      02/07/20248:00AMGlobeNewswire Inc.Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodNASDAQ:ENLVEnlivex Therapeutics Ltd
      01/22/20248:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      01/17/20248:02AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      01/17/20248:00AMGlobeNewswire Inc.Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisNASDAQ:ENLVEnlivex Therapeutics Ltd
      12/20/20238:01AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      11/09/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      11/07/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      11/02/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      10/26/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      09/18/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      09/13/20234:42PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      09/11/20238:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      09/01/20234:30PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      08/02/20238:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      07/31/20238:05AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ENLVEnlivex Therapeutics Ltd
      06/26/20238:03AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
      05/31/20238:10AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
      04/19/20238:03AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
      04/17/20238:04AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
      04/10/20238:01AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:ENLVEnlivex Therapeutics Ltd
      04/04/20238:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:ENLVEnlivex Therapeutics Ltd
       Showing the most relevant articles for your search:NASDAQ:ENLV